VERAXA Biotech Appoints Raju Willener CFO
Analysis based on 9 articles · First reported Sep 04, 2026 · Last updated Sep 08, 2026
The appointment of an experienced CFO is likely viewed positively by investors, potentially supporting the company's capital strategy and pipeline development. However, as a routine executive change, the impact on VERAXA's stock price is expected to be modest.
VERAXA Biotech AG AG, a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as Chief Financial Officer, effective immediately. Willener, who brings over three decades of experience in global capital markets and corporate finance, will report to CEO Christoph Antz. He succeeds Carl von Halem, who was thanked for his support. Willener previously served as CFO of Exentis Group AG, where he led M&A and financial strategy. The appointment is part of VERAXA's efforts to advance its BiTAC platform and oncology pipeline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard